In both PACE and CHARGE, DNA methylation was measured using the Illumina450K Beadchip (Illumina, Inc, CA, USA). In PACE, newborn DNA was extracted from umbilical cord blood in all cohorts except for NFCS, which used neonatal phlebotomy [3 (link)]. In CHARGE, DNA was extracted from whole blood in 14 cohorts, isolated CD4+ T cells in GOLDN, and monocytes (CD14+) in MESA [2 (link)]. In all PACE and CHARGE cohorts, DNA was subjected to bisulfite conversion using Zymo EZ DNA methylation (Zymo Research, CA, USA). Each cohort performed its own quality control removing low quality samples and low quality CpGs, and normalized their untransformed methylation β-values as previously described [2 (link),3 (link)].